

Marcia N Gordon

List of Publications by Year in descending order

Source: [//exaly.com/author-pdf/4335870/publications.pdf](https://exaly.com/author-pdf/4335870/publications.pdf)

Version: 2024-02-01

106
papers

19,581
citations

46636

47
h-index

28046

106
g-index

133
all docs

133
docs citations

133
times ranked

22747
citing authors

#	ARTICLE	IF	CITATIONS
1	A β peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. <i>Nature</i> , 2000, 408, 982-985.	36.2	1,513
2	Increased amyloid- β 42(43) in brains of mice expressing mutant presenilin 1. <i>Nature</i> , 1996, 383, 710-713.	36.2	1,488
3	Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. <i>Nature Medicine</i> , 1998, 4, 97-100.	30.1	1,295
4	Microglial Activation and β -Amyloid Deposit Reduction Caused by a Nitric Oxide-Releasing Nonsteroidal Anti-Inflammatory Drug in Amyloid Precursor Protein Plus Presenilin-1 Transgenic Mice. <i>Journal of Neuroscience</i> , 2002, 22, 2246-2254.	3.8	359
5	Passive immunotherapy against A β in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage. <i>Journal of Neuroinflammation</i> , 2004, 1, 24.	7.4	348
6	Behavioral changes in transgenic mice expressing both amyloid precursor protein and presenilin-1 mutations: lack of association with amyloid deposits. <i>Behavior Genetics</i> , 1999, 29, 177-185.	2.0	323
7	Progressive, age-related behavioral impairments in transgenic mice carrying both mutant amyloid precursor protein and presenilin-1 transgenes. <i>Brain Research</i> , 2001, 891, 42-53.	2.3	313
8	Caloric restriction attenuates A β -deposition in Alzheimer transgenic models. <i>Neurobiology of Aging</i> , 2005, 26, 995-1000.	3.2	313
9	Passive Amyloid Immunotherapy Clears Amyloid and Transiently Activates Microglia in a Transgenic Mouse Model of Amyloid Deposition. <i>Journal of Neuroscience</i> , 2004, 24, 6144-6151.	3.8	293
10	LPS- induced inflammation exacerbates phospho-tau pathology in rTg4510 mice. <i>Journal of Neuroinflammation</i> , 2010, 7, 56.	7.4	241
11	Intracranially Administered Anti- β Antibodies Reduce β -Amyloid Deposition by Mechanisms Both Independent of and Associated with Microglial Activation. <i>Journal of Neuroscience</i> , 2003, 23, 3745-3751.	3.8	236
12	Intrahippocampal LPS injections reduce A β load in APP+PS1 transgenic mice. <i>Neurobiology of Aging</i> , 2001, 22, 1007-1012.	3.2	231
13	Time Course of the Development of Alzheimer-like Pathology in the Doubly Transgenic PS1+APP Mouse. <i>Experimental Neurology</i> , 2002, 173, 183-195.	4.1	230
14	Selectively Reduced Expression of Synaptic Plasticity-Related Genes in Amyloid Precursor Protein + Presenilin-1 Transgenic Mice. <i>Journal of Neuroscience</i> , 2003, 23, 5219-5226.	3.8	225
15	Microglial activation facilitates A β plaque removal following intracranial anti-A β antibody administration. <i>Neurobiology of Disease</i> , 2004, 15, 11-20.	4.5	190
16	Correlation between cognitive deficits and A β deposits in transgenic APP+PS1 mice. <i>Neurobiology of Aging</i> , 2001, 22, 377-385.	3.2	176
17	Dynamic Complexity of the Microglial Activation Response in Transgenic Models of Amyloid Deposition: Implications for Alzheimer Therapeutics. <i>Journal of Neuropathology and Experimental Neurology</i> , 2005, 64, 743-753.	1.8	166
18	Deglycosylated Anti-Amyloid-beta Antibodies Eliminate Cognitive Deficits and Reduce Parenchymal Amyloid with Minimal Vascular Consequences in Aged Amyloid Precursor Protein Transgenic Mice. <i>Journal of Neuroscience</i> , 2006, 26, 5340-5346.	3.8	157

#	ARTICLE	IF	CITATIONS
19	Time-dependent reduction in A β levels after intracranial LPS administration in APP transgenic mice. <i>Experimental Neurology</i> , 2004, 190, 245-253.	4.1	143
20	Microglial Activation is Required for A β Clearance After Intracranial Injection of Lipopolysaccharide in APP Transgenic Mice. <i>Journal of Neuroimmune Pharmacology</i> , 2007, 2, 222-231.	4.0	140
21	A β -1-Antichymotrypsin Promotes A β -Sheet Amyloid Plaque Deposition in a Transgenic Mouse Model of Alzheimer's Disease. <i>Journal of Neuroscience</i> , 2001, 21, 1444-1451.	3.8	134
22	Trafficking CD11b-Positive Blood Cells Deliver Therapeutic Genes to the Brain of Amyloid-Depositing Transgenic Mice. <i>Journal of Neuroscience</i> , 2010, 30, 9651-9658.	3.8	119
23	Ketogenic Diet Improves Motor Performance but Not Cognition in Two Mouse Models of Alzheimer's Pathology. <i>PLoS ONE</i> , 2013, 8, e75713.	2.5	119
24	Behavioral Assessment of Alzheimer's Transgenic Mice Following Long-Term A β Vaccination: Task Specificity and Correlations between A β Deposition and Spatial Memory. <i>DNA and Cell Biology</i> , 2001, 20, 737-744.	2.0	113
25	Neuregulin-1 and ErbB4 Immunoreactivity Is Associated with Neuritic Plaques in Alzheimer Disease Brain and in a Transgenic Model of Alzheimer Disease. <i>Journal of Neuropathology and Experimental Neurology</i> , 2003, 62, 42-54.	1.8	111
26	Histone deacetylase 6 inhibition improves memory and reduces total tau levels in a mouse model of tau deposition. <i>Alzheimer's Research and Therapy</i> , 2014, 6, 12.	6.4	108
27	Diverse microglial responses after intrahippocampal administration of lipopolysaccharide. <i>Glia</i> , 2006, 53, 382-391.	5.3	107
28	Aging enhances classical activation but mitigates alternative activation in the central nervous system. <i>Neurobiology of Aging</i> , 2013, 34, 1610-1620.	3.2	107
29	Exaggerated astrocyte reactivity after nigrostriatal deafferentation in the aged rat. <i>Journal of Comparative Neurology</i> , 1997, 388, 106-119.	2.0	94
30	Number of A β Inoculations in APP+PS1 Transgenic Mice Influences Antibody Titers, Microglial Activation, and Congophilic Plaque Levels. <i>DNA and Cell Biology</i> , 2001, 20, 731-736.	2.0	90
31	Fractalkine overexpression suppresses tau pathology in a mouse model of tauopathy. <i>Neurobiology of Aging</i> , 2013, 34, 1540-1548.	3.2	90
32	Detection of amyloid plaques in mouse models of Alzheimer's disease by magnetic resonance imaging. <i>Magnetic Resonance in Medicine</i> , 2004, 51, 452-457.	3.1	84
33	Biochemical and Histochemical Evidence of Nonspecific Binding of A β 7nAChR Antibodies to Mouse Brain Tissue. <i>Journal of Histochemistry and Cytochemistry</i> , 2004, 52, 1367-1375.	2.6	83
34	Neuropathology of Mice Carrying Mutant APP ^{swe} and/or PS1M146L Transgenes: Alterations in the p75NTR Cholinergic Basal Forebrain Septohippocampal Pathway. <i>Experimental Neurology</i> , 2001, 170, 227-243.	4.1	82
35	Amyloid suppresses induction of genes critical for memory consolidation in APP+PS1 transgenic mice. <i>Journal of Neurochemistry</i> , 2004, 88, 434-442.	4.0	82
36	Divergent changes in D-1 and D-2 dopamine binding sites in human brain during aging. <i>Neurobiology of Aging</i> , 1987, 8, 195-201.	3.2	81

#	ARTICLE	IF	CITATIONS
37	Diverse activation of microglia by chemokine (C-C motif) ligand 2 overexpression in brain. <i>Journal of Neuroinflammation</i> , 2013, 10, 86.	7.4	81
38	Disruption of normal circadian clock function in a mouse model of tauopathy. <i>Experimental Neurology</i> , 2017, 294, 58-67.	4.1	72
39	Convection-enhanced delivery and systemic mannitol increase gene product distribution of AAV vectors 5, 8, and 9 and increase gene product in the adult mouse brain. <i>Journal of Neuroscience Methods</i> , 2010, 194, 144-153.	2.6	66
40	Adeno-associated Viral (AAV) Serotype 5 Vector Mediated Gene Delivery of Endothelin-converting Enzyme Reduces A β Deposits in APP + PS1 Transgenic Mice. <i>Molecular Therapy</i> , 2008, 16, 1580-1586.	8.1	64
41	Partial rescue of memory deficits induced by calorie restriction in a mouse model of tau deposition. <i>Behavioural Brain Research</i> , 2014, 271, 79-88.	2.3	62
42	CCL2 Overexpression in the Brain Promotes Glial Activation and Accelerates Tau Pathology in a Mouse Model of Tauopathy. <i>Frontiers in Immunology</i> , 2020, 11, 997.	4.9	61
43	Dysregulation of Na ⁺ /K ⁺ ATPase by amyloid in APP+PS1 transgenic mice. <i>BMC Neuroscience</i> , 2005, 6, 7.	1.8	60
44	Diversity of transcriptomic microglial phenotypes in aging and Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2022, 18, 360-376.	0.7	56
45	Effective Oral Administration of 17 β -Estradiol to Female C57BL/6J Mice through the Drinking Water. <i>Biology of Reproduction</i> , 1986, 35, 1088-1095.	2.6	47
46	Overcoming antigen masking of anti-amyloidbeta antibodies reveals breaking of B cell tolerance by virus-like particles in amyloidbeta immunized amyloid precursor protein transgenic mice. <i>BMC Neuroscience</i> , 2004, 5, 21.	1.8	47
47	Associative and motor learning in 12-month-old transgenic APP+PS1 mice. <i>Neurobiology of Aging</i> , 2006, 27, 1118-1128.	3.2	47
48	Tau-Directed Immunotherapy: A Promising Strategy for Treating Alzheimer's Disease and Other Tauopathies. <i>Journal of Neuroimmune Pharmacology</i> , 2016, 11, 9-25.	4.0	45
49	Duration and Specificity of Humoral Immune Responses in Mice Vaccinated with the Alzheimer's Disease-Associated A β 1-42 Peptide. <i>DNA and Cell Biology</i> , 2001, 20, 723-729.	2.0	43
50	Intracranial administration of deglycosylated C-terminal-specific anti-A β antibody efficiently clears amyloid plaques without activating microglia in amyloid-depositing transgenic mice. <i>Journal of Neuroinflammation</i> , 2006, 3, 11.	7.4	42
51	Improvement of a low pH antigen-antibody dissociation procedure for ELISA measurement of circulating anti-A β antibodies. <i>BMC Neuroscience</i> , 2007, 8, 22.	1.8	41
52	Diverse Inflammatory Responses in Transgenic Mouse Models of Alzheimer's Disease and the Effect of Immunotherapy on These Responses. <i>ASN Neuro</i> , 2011, 3, AN20110018.	3.0	40
53	Impact of COVID-19 on the Onset and Progression of Alzheimer's Disease and Related Dementias: A Roadmap for Future Research. <i>Alzheimer's and Dementia</i> , 2022, 18, 1038-1046.	0.7	40
54	Sustained Arginase 1 Expression Modulates Pathological Tau Deposits in a Mouse Model of Tauopathy. <i>Journal of Neuroscience</i> , 2015, 35, 14842-14860.	3.8	39

#	ARTICLE	IF	CITATIONS
55	Oral Versus Transdermal Selegiline Antidepressant-Like Activity in Rats. <i>Pharmacology Biochemistry and Behavior</i> , 1999, 63, 501-506.	2.8	36
56	Apparent Behavioral Benefits of Tau Overexpression in P301L Tau Transgenic Mice. <i>Journal of Alzheimer's Disease</i> , 2008, 15, 605-614.	2.7	36
57	Intracranial Injection of AAV Expressing NEP but Not IDE Reduces Amyloid Pathology in APP+PS1 Transgenic Mice. <i>PLoS ONE</i> , 2013, 8, e59626.	2.5	36
58	Epitope analysis following active immunization with tau proteins reveals immunogens implicated in tau pathogenesis. <i>Journal of Neuroinflammation</i> , 2014, 11, 152.	7.4	36
59	Behavioral consequences of ovarian atrophy and estrogen replacement in the APP ^{swe} mouse. <i>Neurobiology of Aging</i> , 2008, 29, 1512-1523.	3.2	33
60	Abnormal post-translational and extracellular processing of brevicin in plaque-bearing mice overexpressing APP ^{sw} . <i>Journal of Neurochemistry</i> , 2010, 113, 784-795.	4.0	33
61	Activation of matrix metalloproteinases following anti-A β immunotherapy; implications for microhemorrhage occurrence. <i>Journal of Neuroinflammation</i> , 2011, 8, 115.	7.4	33
62	Metabolic changes over the course of aging in a mouse model of A β deposition. <i>Neurobiology of Aging</i> , 2016, 44, 62-73.	3.2	33
63	Spermidine/spermine-N1-acetyltransferase ablation impacts tauopathy-induced polyamine stress response. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 58.	6.4	33
64	Increased fibrillar beta-amyloid in response to human clq injections into hippocampus and cortex of APP+PS1 transgenic mice. <i>Neurochemical Research</i> , 2003, 28, 83-93.	3.3	32
65	Suppression of Amyloid Deposition Leads to Long-Term Reductions in Alzheimer's Pathologies in Tg2576 Mice. <i>Journal of Neuroscience</i> , 2009, 29, 4964-4971.	3.8	30
66	Up-regulation of Bcl-2 in APP transgenic mice is associated with neuroprotection. <i>Neurobiology of Disease</i> , 2007, 25, 179-188.	4.5	28
67	Unbiased estimation of cell number using the automatic optical fractionator. <i>Journal of Chemical Neuroanatomy</i> , 2017, 80, A1-A8.	2.2	27
68	CNS-Wide over Expression of Fractalkine Improves Cognitive Functioning in a Tauopathy Model. <i>Journal of NeuroImmune Pharmacology</i> , 2019, 14, 312-325.	4.0	26
69	Deglycosylated Anti-A β Antibody Dose-Response Effects on Pathology and Memory in APP Transgenic Mice. <i>Journal of NeuroImmune Pharmacology</i> , 2008, 3, 187-197.	4.0	23
70	Virus-like Peptide Vaccines Against A β N-terminal or C-Terminal Domains Reduce Amyloid Deposition in APP Transgenic Mice without Addition of Adjuvant. <i>Journal of NeuroImmune Pharmacology</i> , 2010, 5, 133-142.	4.0	19
71	Arginase 1 Insufficiency Precipitates Amyloid- β Deposition and Hastens Behavioral Impairment in a Mouse Model of Amyloidosis. <i>Frontiers in Immunology</i> , 2020, 11, 582998.	4.9	18
72	Topochemical localization of choline acetyltransferase and acetylcholinesterase in mouse brain. <i>Brain Research</i> , 1984, 308, 364-368.	2.3	17

#	ARTICLE	IF	CITATIONS
73	Effects of Repetitive Exposure to Anesthetics and Analgesics in the Tg2576 Mouse Alzheimer's Model. <i>Neurotoxicity Research</i> , 2014, 26, 414-421.	2.7	17
74	Toward Development of Neuron Specific Transduction After Systemic Delivery of Viral Vectors. <i>Frontiers in Neurology</i> , 2021, 12, 685802.	2.5	17
75	A β 2 and perlecan in rat brain: glial activation, gradual clearance and limited neurotoxicity. <i>Mechanisms of Ageing and Development</i> , 2000, 112, 135-152.	4.6	16
76	Amyloid, hyperactivity, and metabolism: Theoretical comment on Vloeberghs et al. (2008). <i>Behavioral Neuroscience</i> , 2008, 122, 730-732.	1.2	15
77	Oligomeric tau-targeted immunotherapy in Tg4510 mice. <i>Alzheimer's Research and Therapy</i> , 2017, 9, 46.	6.4	14
78	Regional and Cellular Localization of Presenilin-2 RNA in Rat and Human Brain. <i>Experimental Neurology</i> , 1997, 145, 555-564.	4.1	13
79	Impaired spatial navigation learning in transgenic mice over-expressing heme oxygenase-1. <i>Brain Research</i> , 1998, 808, 110-112.	2.3	13
80	Ontogeny of glycerol phosphate dehydrogenase-positive oligodendrocytes in rat brain. Impaired differentiation of oligodendrocytes in the myelin deficient mutant rat. <i>International Journal of Developmental Neuroscience</i> , 1992, 10, 243-253.	1.6	11
81	Rats receiving systemic 3-nitropropionic acid demonstrate impairment of memory in Morris water maze. <i>Cognitive, Affective and Behavioral Neuroscience</i> , 1999, 27, 561-566.	1.4	11
82	Chronological Age Impacts Immunotherapy and Monocyte Uptake Independent of Amyloid Load. <i>Journal of NeuroImmune Pharmacology</i> , 2012, 7, 202-214.	4.0	10
83	Myeloid Arginase 1 Insufficiency Exacerbates Amyloid- β 2 Associated Neurodegenerative Pathways and Glial Signatures in a Mouse Model of Alzheimer's Disease: A Targeted Transcriptome Analysis. <i>Frontiers in Immunology</i> , 2021, 12, 628156.	4.9	10
84	Low-Dose Delta-9-Tetrahydrocannabinol as Beneficial Treatment for Aged APP/PS1 Mice. <i>International Journal of Molecular Sciences</i> , 2022, 23, 2757.	4.2	10
85	An Immunomodulatory Therapeutic Vaccine Targeting Oligomeric Amyloid- β 21. <i>Journal of Alzheimer's Disease</i> , 2020, 77, 1639-1653.	2.7	9
86	Accumulation of C-terminal cleaved tau is distinctly associated with cognitive deficits, synaptic plasticity impairment, and neurodegeneration in aged mice. <i>GeroScience</i> , 2022, 44, 173-194.	4.7	9
87	Spontaneous tumors in aging female mice are more prevalent in the lateral pituitary zones. <i>Neurobiology of Aging</i> , 1987, 8, 67-70.	3.2	7
88	Synthetic lethality of PARP inhibition in BRCA-network disrupted tumor cells is associated with interferon pathway activation and enhanced by interferon- β . <i>Apoptosis: an International Journal on Programmed Cell Death</i> , 2012, 17, 691-701.	4.9	7
89	Adeno associated viral-mediated intraosseous labeling of bone marrow derived cells for CNS tracking. <i>Journal of Immunological Methods</i> , 2016, 432, 51-56.	1.4	6
90	Convection Enhanced Delivery of Recombinant Adeno-associated Virus into the Mouse Brain. <i>Methods in Molecular Biology</i> , 2016, 1382, 285-295.	0.0	6

#	ARTICLE	IF	CITATIONS
91	Contrasting In Vivo Effects of Two Peptide-Based Amyloid- β Protein Aggregation Inhibitors in a Transgenic Mouse Model of Amyloid Deposition. <i>Cell Transplantation</i> , 2008, 17, 397-408.	2.6	5
92	Intraventricular Human Immunoglobulin Distributes Extensively but Fails to Modify Amyloid in a Mouse Model of Amyloid Deposition. <i>Current Alzheimer Research</i> , 2014, 11, 664-671.	1.5	5
93	Pituitary and Hypothalamic Glucose-6-Phosphate Dehydrogenase: Effects of Estradiol and Age in C57BL/6J Mice*. <i>Endocrinology</i> , 1988, 122, 726-733.	2.8	4
94	Mice Transgenic for a Human Amyloid Precursor Protein Promoter-lacZ Reporter Construct: Appropriate Cell-Type Expression, But Not Regulation in Brain. <i>Journal of Molecular Neuroscience</i> , 1999, 13, 111-120.	2.4	4
95	Dendritic and Langerhans cells respond to A β peptides differently: implication for AD immunotherapy. <i>Oncotarget</i> , 2015, 6, 35443-35457.	2.1	4
96	The Memory Benefit to Aged APP/PS1 Mice from Long-Term Intranasal Treatment of Low-Dose THC. <i>International Journal of Molecular Sciences</i> , 2022, 23, 4253.	4.2	4
97	Genotypic influences on pituitary responsiveness to haloperidol in mice. <i>Psychoneuroendocrinology</i> , 1987, 12, 211-218.	2.8	2
98	Neural atrophy produced by AAV tau injections into hippocampus and anterior cortex of middle-aged mice. <i>Neurobiology of Aging</i> , 2023, 124, 39-50.	3.2	2
99	New approaches to the study of central nervous system function. Immune-nervous system interactions and cell culture. <i>Neurobiology of Aging</i> , 1988, 9, 763-765.	3.2	1
100	The Association of Microglial Activation and Amyloid Reduction in APP+PS1 Transgenic Mice. <i>Current Medicinal Chemistry Immunology, Endocrine & Metabolic Agents</i> , 2003, 3, 27-32.	0.2	0
101	The H-2 receptor antagonist cimetidine blocks kainic acid toxicity in hippocampus as effectively as the NMDA receptor antagonist MK-801. <i>Journal of Neuropathology and Experimental Neurology</i> , 2007, 66, 420.	1.8	0
102	Organization and Function of the Central Nervous System. , 2007, , 1-8.		0
103	P3-007: Characterization of full length and c-terminal truncated tau pathological progression with age in wild type mice. <i>Alzheimer's and Dementia</i> , 2015, 11, P621-P622.	0.7	0
104	P3-176: AGE AS A PREDICTOR OF DIFFERENT PHYSIOLOGICAL FORMS OF TAU. <i>Alzheimer's and Dementia</i> , 2018, 14, P1135.	0.7	0
105	The H β 2 Receptor Antagonist Cimetidine Blocks Kainic Acid Toxicity in Hippocampus as Effectively as the NMDA Receptor Antagonist MK-801. <i>FASEB Journal</i> , 2007, 21, A20.	0.5	0
106	Induction of tauopathy in a mouse model of amyloidosis using intravenous administration of adeno-associated virus vectors expressing human P301L tau. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2024, 10, .	3.9	0